Archives
Provisional finding in hydrocortisone competition case
There’s been a provisional finding by the Competition and Markets Authority (CMA) in the important hydrocortisone competition case, with a Statement of Objections issued.
In the coming weeks, the CMA expect written and oral representations to be made following the Statement of Objections that’s been issued.
The provisional findings of the CMA are incredibly worrying. It all comes down whether the two companies at the heart of the investigation colluded in order to charge higher prices and make bigger profits; all at the expense of our NHS, and our hard-earned tax money.
Boots overcharging the NHS for pain-relief mouthwash
Boots overcharging the NHS for pain relief mouthwash is a serious allegation that must be closely investigated.
The allegations are that the company behind high-street chain Boots, Walgreens Boots Alliance, are reportedly overcharging the NHS by almost 3,500% for pain-relieving mouthwash used by cancer patients.
The Competition and Markets Authority (CMA) are considering the issue and health Minister, Steve Brine, is calling for an urgent investigation.
Vital Hydrocortisone tablets at the centre of suspected excessive and unfair pricing to the NHS
The Competition and Markets Authority (CMA) are investigating price-hikes of vital hydrocortisone tablets on the basis that they suspect they are being excessively inflated.
Intas Pharmaceuticals Limited and Accord Healthcare Limited, which acquired Actavis UK in January 2017, are at the centre of the CMA’s investigations. The suspicion is breaches of competition laws through unfair prices over the supply of hydrocortisone tablets in the UK to the NHS.
Read More